

HR 7473

Generic Substitution Noninterference Act

Congress: 117 (2021–2023, Ended)

Chamber: House

Policy Area: Health

Introduced: Apr 7, 2022

Current Status: Referred to the Subcommittee on Antitrust, Commercial, and Administrative Law.

Latest Action: Referred to the Subcommittee on Antitrust, Commercial, and Administrative Law. (Nov 1, 2022)

Official Text: <https://www.congress.gov/bill/117th-congress/house-bill/7473>

Sponsor

Name: Rep. Maloney, Carolyn B. [D-NY-12]

Party: Democratic • **State:** NY • **Chamber:** House

Cosponsors (7 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Cicilline, David N. [D-RI-1]	D · RI		Apr 7, 2022
Rep. DeSaulnier, Mark [D-CA-11]	D · CA		Apr 7, 2022
Rep. Nadler, Jerrold [D-NY-10]	D · NY		Apr 7, 2022
Rep. Porter, Katie [D-CA-45]	D · CA		Apr 7, 2022
Rep. Raskin, Jamie [D-MD-8]	D · MD		Apr 7, 2022
Rep. Schakowsky, Janice D. [D-IL-9]	D · IL		Apr 7, 2022
Rep. Welch, Peter [D-VT-At Large]	D · VT		Apr 7, 2022

Committee Activity

Committee	Chamber	Activity	Date
Judiciary Committee	House	Referred to	Nov 1, 2022

Subjects & Policy Tags

Policy Area:

Health

Related Bills

No related bills are listed.

Generic Substitution Noninterference Act

This bill prohibits drug manufacturers from helping or directing health care providers to limit prescriptions to brand-name drugs when generic versions are available. The Federal Trade Commission and states may enforce this bill through civil actions.

Actions Timeline

- **Nov 1, 2022:** Referred to the Subcommittee on Antitrust, Commercial, and Administrative Law.
- **Apr 7, 2022:** Introduced in House
- **Apr 7, 2022:** Referred to the House Committee on the Judiciary.